# Clinical Trials Data EGFR - Document 74

# A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI

## Clinical Trial: https://clinicaltrials.gov/study/NCT01763307

"eligibilityCriteria": "Inclusion Criteria:\n\n\* metastatic colon cancer patients\n\* male or female\n\* age\\> 18\n\* treated EGFRI\n\nExclusion Criteria:\n\n\* prior treatment with EGFRI",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with an EGFR gene mutation would not be directly excluded. The key criteria to consider are:  
  
- \*\*Inclusion Criteria:\*\* The trial is for metastatic colon cancer patients who have been treated with EGFR inhibitors (EGFRI).  
- \*\*Exclusion Criteria:\*\* Patients who have received prior treatment with EGFR inhibitors are not eligible.  
  
Therefore, a patient's eligibility depends on their treatment history with EGFR inhibitors rather than their genetic mutation status. If the patient has not had prior treatment with EGFR inhibitors, they may be eligible for the trial. However, if they have already been treated with EGFR inhibitors, they would not be eligible.